Literature DB >> 20399901

Chondroitin sulfate improves synovitis in rabbits with chronic antigen-induced arthritis.

R Largo1, J A Roman-Blas, J Moreno-Rubio, O Sánchez-Pernaute, M J Martínez-Calatrava, S Castañeda, G Herrero-Beaumont.   

Abstract

OBJECTIVE: Our aim was to explore the effect of chondroitin sulfate (CS), a natural glycosaminoglycan with attributed anti-inflammatory properties, on synovitis in a rabbit model of chronic arthritis with intense systemic inflammation bolstered by endothelial lesion and atherosclerotic diet.
METHODS: Chronic arthritis was induced by intraarticular injections of ovalbumin in immunized rabbits. Systemic inflammation was boosted in these rabbits by receiving a hyperlipidemic diet after producing an endothelial lesion in the femoral arteries. A group of these rabbits were treated with CS (100mg/kg/day). At sacrifice, synovial membranes were isolated, and cyclooxygenase-2 (COX-2) and chemokine (C-C motif) ligand 2 (CCL2) mRNA, as well as protein expression were assayed by quantitative real-time polymerase chain reaction (RT-PCR) and western blot studies. Histological synovial examination was also carried out employing the histopathological synovitis score (Krenn scale).
RESULTS: CS diminished both gene expression and protein synthesis of COX-2 and CCL2, and the histopathological score of the synovial membrane, when compared to untreated rabbits. In fact, CS partially prevented the intimal layer proliferation and the inflammatory cell infiltration in the synovial membrane, which was observed in non-treated animals.
CONCLUSION: CS reduced the inflammatory response of the synovial membrane, as well as decreased the synovial histopathological lesions in our animal model. Further studies are warranted to demonstrate whether CS might be beneficial in the treatment of inflammatory arthritis. Copyright 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20399901     DOI: 10.1016/j.joca.2010.01.017

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  6 in total

1.  Osteoarthritis: Chondroitin sulfate - CONCEPT clear, uncertainties unchanged.

Authors:  Gabriel Herrero-Beaumont; Raquel Largo
Journal:  Nat Rev Rheumatol       Date:  2017-08-17       Impact factor: 20.543

Review 2.  Chondroitin sulphate: a focus on osteoarthritis.

Authors:  Mamta Bishnoi; Ankit Jain; Pooja Hurkat; Sanjay K Jain
Journal:  Glycoconj J       Date:  2016-05-19       Impact factor: 2.916

3.  Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.

Authors:  Lukas Martin Wildi; Jean-Pierre Raynauld; Johanne Martel-Pelletier; André Beaulieu; Louis Bessette; Frédéric Morin; François Abram; Marc Dorais; Jean-Pierre Pelletier
Journal:  Ann Rheum Dis       Date:  2011-03-01       Impact factor: 19.103

4.  Structural Morphology of Rabbit Patella and Suprapatella Cartilage by Microscopic MRI and Polarized Light Microscopy.

Authors:  Hannah Mantebea; Syeda Batool; Mouhamad Hammami; Yang Xia
Journal:  Cartilage       Date:  2021-02-08       Impact factor: 3.117

5.  Evaluation of antigen-induced synovitis in a porcine model: Immunological, arthroscopic and kinetic studies.

Authors:  Francisco-Javier Vela; Francisco-Miguel Sánchez-Margallo; Rebeca Blázquez; Verónica Álvarez; Raquel Tarazona; M Teresa Mangas-Ballester; Alejandro Cristo; Javier G Casado
Journal:  BMC Vet Res       Date:  2017-04-07       Impact factor: 2.741

6.  Reduction of osteoarthritis severity in the temporomandibular joint of rabbits treated with chondroitin sulfate and glucosamine.

Authors:  Felipe Ernesto Artuzi; Edela Puricelli; Carlos Eduardo Baraldi; Alexandre Silva Quevedo; Deise Ponzoni
Journal:  PLoS One       Date:  2020-04-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.